Centessa Pharmaceuticals PLC

NASDAQ:CNTAUnited States

Centessa Pharmaceuticals plc is a United Kingdom-based clinical-stage pharmaceutical company. Its advanced programs include a hemophilia program, an orexin agonist program for the treatment of narcolepsy and other sleep-wake disorders, and an immuno-oncology program focused on its LockBody technology platform. SerpinPC, its advanced product candidate, is an investigational, potentially first-in-class subcutaneously administered novel inhibitor of activated protein C for hemophilia. Its Orexin Receptor 2 (OX2R) Agonist Program includes ORX750, which is an investigational, orally administered, selective OX2R agonist designed to directly target the underlying pathophysiology of orexin neuron loss in narcolepsy type 1 and to address sleep-wake disorders with normal orexin levels such as narcolepsy type 2 and idiopathic hypersomnia. It is also exploring follow-up orexin agonists for potential expansion opportunities into a range of sleep-wake disorders and broader neurological indications.

Contact Information

Headquarters

3Rd Floor, 1 Ashley RoadALTRINCHAM, United Kingdom WA14 2DT

Phone

---

Fax

---

Executives

Independent Chairman of the Board

Francesco de Rubertis

Chief Executive Officer, Director

Saurabh Saha

Chief Financial Officer

John Crowley

Chief People Officer

Karen Anderson

Executive Vice President and Chairman of Development

Antoine Yver